Renovaro (RENB) Competitors $0.65 -0.02 (-3.65%) Closing price 03/27/2025 04:00 PM EasternExtended Trading$0.65 +0.00 (+0.08%) As of 07:55 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock RENB vs. AUTL, TRML, STOK, DNA, ZVRA, RGNX, PHAT, SIGA, ERAS, and HUMAShould you be buying Renovaro stock or one of its competitors? The main competitors of Renovaro include Autolus Therapeutics (AUTL), Tourmaline Bio (TRML), Stoke Therapeutics (STOK), Ginkgo Bioworks (DNA), Zevra Therapeutics (ZVRA), REGENXBIO (RGNX), Phathom Pharmaceuticals (PHAT), SIGA Technologies (SIGA), Erasca (ERAS), and Humacyte (HUMA). These companies are all part of the "pharmaceutical products" industry. Renovaro vs. Autolus Therapeutics Tourmaline Bio Stoke Therapeutics Ginkgo Bioworks Zevra Therapeutics REGENXBIO Phathom Pharmaceuticals SIGA Technologies Erasca Humacyte Autolus Therapeutics (NASDAQ:AUTL) and Renovaro (NASDAQ:RENB) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, earnings, institutional ownership, profitability, community ranking, valuation, analyst recommendations, risk and dividends. Does the MarketBeat Community prefer AUTL or RENB? Autolus Therapeutics received 228 more outperform votes than Renovaro when rated by MarketBeat users. CompanyUnderperformOutperformAutolus TherapeuticsOutperform Votes22868.06% Underperform Votes10731.94% RenovaroN/AN/A Do analysts prefer AUTL or RENB? Autolus Therapeutics presently has a consensus target price of $9.52, indicating a potential upside of 476.97%. Given Autolus Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Autolus Therapeutics is more favorable than Renovaro.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Autolus Therapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00Renovaro 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has stronger earnings & valuation, AUTL or RENB? Renovaro has lower revenue, but higher earnings than Autolus Therapeutics. Autolus Therapeutics is trading at a lower price-to-earnings ratio than Renovaro, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAutolus Therapeutics$10.12M43.38-$208.38M-$0.86-1.92RenovaroN/AN/A-$80.65M-$0.93-0.70 Is AUTL or RENB more profitable? Renovaro's return on equity of -61.84% beat Autolus Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Autolus TherapeuticsN/A -63.65% -36.54% Renovaro N/A -61.84%-48.07% Do institutionals and insiders hold more shares of AUTL or RENB? 72.8% of Autolus Therapeutics shares are held by institutional investors. Comparatively, 71.4% of Renovaro shares are held by institutional investors. 25.7% of Autolus Therapeutics shares are held by company insiders. Comparatively, 21.7% of Renovaro shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Which has more risk & volatility, AUTL or RENB? Autolus Therapeutics has a beta of 2.07, suggesting that its stock price is 107% more volatile than the S&P 500. Comparatively, Renovaro has a beta of 0.42, suggesting that its stock price is 58% less volatile than the S&P 500. Does the media prefer AUTL or RENB? In the previous week, Autolus Therapeutics had 19 more articles in the media than Renovaro. MarketBeat recorded 20 mentions for Autolus Therapeutics and 1 mentions for Renovaro. Renovaro's average media sentiment score of 1.87 beat Autolus Therapeutics' score of 0.66 indicating that Renovaro is being referred to more favorably in the news media. Company Overall Sentiment Autolus Therapeutics Positive Renovaro Very Positive SummaryAutolus Therapeutics beats Renovaro on 11 of the 15 factors compared between the two stocks. Remove Ads Get Renovaro News Delivered to You Automatically Sign up to receive the latest news and ratings for RENB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RENB vs. The Competition Export to ExcelMetricRenovaroPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$103.09M$6.92B$5.65B$8.06BDividend YieldN/A2.72%4.57%4.01%P/E Ratio-0.707.2023.1419.03Price / SalesN/A226.01385.7893.17Price / CashN/A65.6738.1634.64Price / Book1.256.476.934.33Net Income-$80.65M$141.90M$3.20B$247.06M7 Day Performance-7.28%-3.20%-2.30%-0.37%1 Month Performance-33.90%-5.64%2.86%-3.85%1 Year Performance-75.49%-7.47%10.66%1.27% Renovaro Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RENBRenovaro1.2747 of 5 stars$0.65-3.6%N/A-76.7%$103.09MN/A-0.7020Positive NewsAUTLAutolus Therapeutics2.8266 of 5 stars$1.71+0.6%$9.52+456.7%-73.6%$455.02M$10.12M-1.41330Positive NewsTRMLTourmaline Bio1.9928 of 5 stars$17.61+2.7%$50.00+183.9%-26.9%$452.31MN/A-6.2444Positive NewsSTOKStoke Therapeutics3.7351 of 5 stars$8.29+1.7%$23.00+177.4%-47.4%$448.31M$36.56M-3.95100Earnings ReportAnalyst RevisionDNAGinkgo Bioworks0.6567 of 5 stars$7.68+5.7%$4.58-40.5%N/A$445.93M$227.04M-0.59640ZVRAZevra Therapeutics3.0403 of 5 stars$8.21+2.5%$22.29+171.4%+34.0%$444.29M$23.61M-4.1720RGNXREGENXBIO4.504 of 5 stars$8.70+5.6%$33.88+289.4%-64.3%$435.75M$83.33M-1.73370Analyst RevisionPHATPhathom Pharmaceuticals3.6114 of 5 stars$6.55+5.1%$22.17+238.4%-39.5%$433.84M$55.25M-1.15110SIGASIGA Technologies2.5817 of 5 stars$5.98+6.6%N/A-34.5%$427.19M$138.72M4.9840Positive NewsERASErasca3.6638 of 5 stars$1.49-2.6%$4.80+222.1%-24.8%$421.26MN/A-1.80120Analyst ForecastNews CoverageHUMAHumacyte2.165 of 5 stars$3.32flat$13.71+313.1%-35.2%$417.85M$1.57M-2.48150Upcoming EarningsAnalyst ForecastNews Coverage Remove Ads Related Companies and Tools Related Companies Autolus Therapeutics Alternatives Tourmaline Bio Alternatives Stoke Therapeutics Alternatives Ginkgo Bioworks Alternatives Zevra Therapeutics Alternatives REGENXBIO Alternatives Phathom Pharmaceuticals Alternatives SIGA Technologies Alternatives Erasca Alternatives Humacyte Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RENB) was last updated on 3/28/2025 by MarketBeat.com Staff From Our PartnersElon Warns: Exec Order 14024 Targets DollarExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredNew “Trump” currency proposed in DCAccording to one of the most connected men in Washington… A surprising new bill was just introduced in Wash...Paradigm Press | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | SponsoredElon Musk is helping print “new gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredTwo Unmistakable Patterns Return…The signs suggest we're entering one of those rare periods now. That's why Central Banks are buying gold at...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Renovaro Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Renovaro With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
